Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 12;17(16):5840.
doi: 10.3390/ijerph17165840.

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

Salvatore Santo Signorelli  1   2 , Ingrid Platania  2 , Salvatore Davide Tomasello  3 , Marco Mangiafico  1 , Giuliana Barcellona  1   2 , Domenico Di Raimondo  4 , Agostino Gaudio  1
Affiliations
Review

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

Salvatore Santo Signorelli et al. Int J Environ Res Public Health. .

Abstract

Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the review were organized to show both benefits or consequences from antiplatelet pharmacotherapy. Conclusively, this review provides a potential synopsis on the most appropriate therapeutic approach for stroke prevention in clinical practice.

Keywords: aspirin; cilostazol; clopidogrel; combined drug therapy; dipyridamole; prevention; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Born G., Patrono C. Antiplatelet drugs. Br. J. Pharmacol. 2009;147(Suppl. S1):S241–S251. doi: 10.1038/sj.bjp.0706401. - DOI - PMC - PubMed
    1. Wood A.J., Patrono C. Aspirin as an Antiplatelet Drug. N. Engl. J. Med. 1994;330:1287–1294. doi: 10.1056/NEJM199405053301808. - DOI - PubMed
    1. Fowkes G., Price J.F., Stewart M.C.W., Butcher I., Leng G.C., Pell A.C.H., Sandercock P., Fox K.A.A., Lowe G.D.O., Murray G.D., et al. Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial. JAMA. 2010;303:841–848. doi: 10.1001/jama.2010.221. - DOI - PubMed
    1. Wang Y., Wang Y., Zhao X., Liu L., Wang D., Wang C., Wang C., Li H., Meng X., Cui L., et al. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. N. Engl. J. Med. 2013;369:11–19. doi: 10.1056/NEJMoa1215340. - DOI - PubMed
    1. Gouya G., Arrich J., Wolzt M., Huber K., Verheugt F.W., Gurbel P.A., Pirker-Kees A., Siller-Matula J.M. Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases. Stroke. 2014;45:492–503. doi: 10.1161/STROKEAHA.113.002590. - DOI - PubMed

Substances